RTI Biologics, Inc. (RTIX) Tops Q1 EPS by 1c; Guides Q2, Updates FY12
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Join SI Premium – FREE
RTI Biologics, Inc. (NASDAQ: RTIX) reported Q1 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $43.7 million versus the consensus estimate of $41.91 million.
RTI Biologics, Inc. sees Q2 2012 EPS of $0.04, versus the consensus of $0.04. RTI Biologics, Inc. sees Q2 2012 revenue of $43-$44 million, versus the consensus of $44.18 million.
RTI Biologics, Inc. sees FY2012 EPS of $0.16-$0.17, versus prior guidance of $0.15-$0.17 and the consensus of $0.16. RTI Biologics, Inc. sees FY2012 revenue of $176-$178 million, versus the consensus of $175.7 million.
For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.
RTI Biologics, Inc. sees Q2 2012 EPS of $0.04, versus the consensus of $0.04. RTI Biologics, Inc. sees Q2 2012 revenue of $43-$44 million, versus the consensus of $44.18 million.
RTI Biologics, Inc. sees FY2012 EPS of $0.16-$0.17, versus prior guidance of $0.15-$0.17 and the consensus of $0.16. RTI Biologics, Inc. sees FY2012 revenue of $176-$178 million, versus the consensus of $175.7 million.
For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
- Pharvaris B.V. (PHVS) PT Raised to $75 at Citizens: Has Cash Runway Into 2028
- Morgan Stanley Upgrades Oil India Ltd. (OINL:IN) to Equalweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
